Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study

Anti-CD20 antibody treatments, such as obinutuzumab, have been associated with infusion-related reactions (IRRs). In the phase 3 iLLUMINATE study of ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab in first-line chronic lymphocytic leukemia/small lymphocytic lymphoma, IRRs were substantially...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Ann Hematol
Huvudupphovsmän: Greil, Richard, Tedeschi, Alessandra, Moreno, Carol, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Gill, Devinder, Gribben, John G., Flinn, Ian W., Wang, Zhengyuan, Cheung, Leo W. K., Nguyen, Aaron N., Zhou, Cathy, Styles, Lori, Demirkan, Fatih
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer Berlin Heidelberg 2021
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8195966/
https://ncbi.nlm.nih.gov/pubmed/34018029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-021-04536-6
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk